In this scenario, co-upregulation of MAPK14 (together with ATF2) might enable the competitive edge for MAPK14- as compared to ATM-mediated ATF2 activation, thereby driving tumor progression and drug resistance [40]. This evidence concerns the gene MAPK14 and neoplasm.